Currently Viewing:
Newsroom
Currently Reading
Bone Marrow Environment in Patients With RA May Promote Inflammation
December 12, 2017 – Kelly Davio
Researchers Say Medicare Advantage Plans Need Better Incentives to Meet Future Demand
December 12, 2017 – Allison Inserro
University, Genetics Firm Find Link Between ADHD, Delay Discounting
December 12, 2017 – Allison Inserro
Welltok Identifies Who's at Risk for Getting and Spreading the Flu
December 12, 2017 – Jaime Rosenberg
What We're Reading: Medical Device Approval; Medical Laboratories Sue Government; ACA Sign-Up Deadline
December 12, 2017 – AJMC Staff
What's the Magic Payment Mix for Medicare Primary Care Providers?
December 11, 2017 – Allison Inserro
Racial Disparities Prevalent in Survival of Patients With Ovarian, Colon, and Breast Cancer
December 11, 2017 – Jaime Rosenberg
Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval
December 11, 2017 – Mary Caffrey
The Past, Present, and Future of HIV Funding
December 11, 2017 – Jaime Rosenberg

Study: Body Fat Composition May Predict Poor Treatment Outcomes in Patients With Multiple Myeloma

Kelly Davio
A recent study found that excess body fat in the abdomen and pelvis may predict poor treatment response in patients with multiple myeloma.
While studies have demonstrated that excess body weight is a risk factor for both the incidence and mortality of multiple myeloma (MM), to date, the correlation between body fat composition and disease activity, adverse events, and treatment response has not been well investigated. A recent study, published in Oncotarget, found that excess body fat in the abdomen and pelvis may predict poor treatment response in patients with MM.

The study followed a subgroup of 108 patients with MM who were enrolled in the prospective GMMG-MM5 trial. The patients received whole-body low-dose computed tomography (WBLDCT) that measured body fat composition prior to induction therapy.

In each patient, body fat was divided into the areas of abdomen, pelvis, and thigh. Total adipose tissue (TAT) was categorized as either subcutaneous (SAT) or visceral (VAT). The researchers assessed the relationship between these body fat parameters and disease activity, cytogenetics, adverse events, and treatment response.

The researchers found that baseline hemoglobin levels correlated significantly with abdominal TAT and VAT, as well as with abdominal VAT. Furthermore, a significant correlation was found between osteopenia and abdominal TAT and SAT, as well as with pelvic TAT. Finally, a reciprocal correlation was observed between adverse cytogenetics and abdominal and pelvic VAT.

In terms of treatment outcomes, 42 patients achieved a very good partial response (VGPR) or better, while 55 patients reached a partial response (PR) or worse. Treatment response was negatively correlated to abdominal and pelvic VAT. In contrast to body fat composition, body mass index did not show a significant association with treatment response.

The researchers did not identify a correlation between body fat parameters and disease activity; calcium, renal, anemia, and bone (CRAB) criteria; or adverse events.

The researchers concluded that there was a clinically relevant difference in the treatment outcomes of patients depending upon VAT and SAT, and that excessive body fat in the pelvis could be a predictive factor for poor treatment response. Further studies are necessary, they say, in order to investigate this apparent relationship and to assess the role of weight gain or loss over the course of treatment for MM. Additional influences that warrant further investigation, according to the study, include comorbidities, chemotherapy dosing, and the interaction of drugs with body fat metabolism.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!